Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Bowen

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
Haematologica|April 1, 2014
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)Leonie Saft, Mohsen Karimi, Mehran Ghaderi, et al.
Blood Advances|September 7, 2021
Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologistsIgor Stojkov, Annette Conrads-Frank, Ursula Rochau, et al.
Applied and Environmental Microbiology|December 14, 2020
Cry75Aa (Mpp75Aa) Insecticidal Proteins for Controlling the Western Corn Rootworm, <i>Diabrotica virgifera virgifera</i>, (Coleoptera: Chrysomelidae), Isolated from the Insect Pathogenic Bacteria <i>Brevibacillus laterosporus</i>David Bowen, Yong Yin, Stanislaw Flasinski, et al.
The Journal of Clinical Endocrinology and Metabolism|June 7, 2002
Frequent occurrence of an intron 4 mutation in multiple endocrine neoplasia type 1Jeremy J O Turner, Poloko D Leotlela, Anna A J Pannett, et al.
Annals of Hematology|April 11, 2012
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromesFelicitas Thol, Haiyang Yun, Ann-Kathrin Sonntag, et al.
British Journal of Haematology|June 28, 2021
British Society for Haematology guidelines for the management of adult myelodysplastic syndromesSally B Killick, Wendy Ingram, Dominic Culligan, et al.
British Journal of Haematology|June 17, 2021
British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic SyndromesSally B Killick, Daniel H Wiseman, Lynn Quek, et al.
The Lancet. Oncology|September 26, 2015
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort studyFabio Efficace, Gianluca Gaidano, Massimo Breccia, et al.
American Journal of Hematology|December 21, 2023
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studiesRena Buckstein, Jeannie Callum, Anca Prica, et al.
Clinical Pharmacokinetics|April 22, 2025
Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19Darren M Roberts, Xin Liu, Suzanne L Parker, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
Haematologica|April 1, 2014
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)Leonie Saft, Mohsen Karimi, Mehran Ghaderi, et al.
Blood Advances|September 7, 2021
Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologistsIgor Stojkov, Annette Conrads-Frank, Ursula Rochau, et al.
Applied and Environmental Microbiology|December 14, 2020
Cry75Aa (Mpp75Aa) Insecticidal Proteins for Controlling the Western Corn Rootworm, <i>Diabrotica virgifera virgifera</i>, (Coleoptera: Chrysomelidae), Isolated from the Insect Pathogenic Bacteria <i>Brevibacillus laterosporus</i>David Bowen, Yong Yin, Stanislaw Flasinski, et al.
The Journal of Clinical Endocrinology and Metabolism|June 7, 2002
Frequent occurrence of an intron 4 mutation in multiple endocrine neoplasia type 1Jeremy J O Turner, Poloko D Leotlela, Anna A J Pannett, et al.
Annals of Hematology|April 11, 2012
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromesFelicitas Thol, Haiyang Yun, Ann-Kathrin Sonntag, et al.
British Journal of Haematology|June 28, 2021
British Society for Haematology guidelines for the management of adult myelodysplastic syndromesSally B Killick, Wendy Ingram, Dominic Culligan, et al.
British Journal of Haematology|June 17, 2021
British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic SyndromesSally B Killick, Daniel H Wiseman, Lynn Quek, et al.
The Lancet. Oncology|September 26, 2015
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort studyFabio Efficace, Gianluca Gaidano, Massimo Breccia, et al.
American Journal of Hematology|December 21, 2023
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studiesRena Buckstein, Jeannie Callum, Anca Prica, et al.
Clinical Pharmacokinetics|April 22, 2025
Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19Darren M Roberts, Xin Liu, Suzanne L Parker, et al.
Pageof 10